Article Text

PDF
▼Drotrecogin alfa (activated) for severe sepsis

Abstract

Sepsis, the systemic inflammatory response to infection, is common among severely ill patients and can be life-threatening. Over a quarter of patients in UK intensive care units (ICUs) have severe sepsis in the first 24 hours after admission.1 Of these, 35% die before leaving the ICU and 47% before leaving hospital despite standard therapy.1 ▼Drotrecogin alfa (activated) (Xigris - Eli Lilly), a recombinant human activated protein C, is licensed for treating adults who have severe sepsis with multiple organ failure. Here we assess its efficacy and safety.

Statistics from Altmetric.com

  • Relevant BNF section: 2.11

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.